Epigenomics AG Reports Successful Completion and Positive Results from Prostate Cancer Clinical Study
PITX2 biomarker classifies patients into groups at high and low risk for relapse
20-Oct-2008 -
Epigenomics AG reported positive final results from its prognostic prostate cancer study.
“After testing all patient samples for methylation in the PITX2 gene we have successfully conducted our final analysis”, commented Dr. Gunter Weiss, Vice President Product Development at Epigenomics. “This ...
Affymetrix
Marker
methylation
+3